Walborn Amanda, Williams Mark, Fareed Jawed, Hoppensteadt Debra
1 Department of Pathology, Loyola University Medical Center, Maywood, IL, USA.
2 Department of Pharmacology, Loyola University Medical Center, Maywood, IL, USA.
Clin Appl Thromb Hemost. 2018 Oct;24(7):1033-1041. doi: 10.1177/1076029618772353. Epub 2018 May 30.
The development of coagulation abnormalities is common in patients with sepsis. Sepsis-associated coagulopathy (SAC) is typically diagnosed by prothrombin time (PT) prolongation or elevated international normalized ratio (INR) in conjunction with reduced platelet count. INR is also used to monitor warfarin-treated patients. However, due to the different natures of SAC and warfarin anticoagulation, it is likely that the same INR value provides different information in these two patient populations. The purpose of this study was to compare measures of coagulation function and clotting factor levels in patients with SAC to those observed in patients receiving warfarin anticoagulation. Deidentified plasma samples were collected at baseline from patients diagnosed with SAC and from patients receiving warfarin. These plasma samples were evaluated for PT/INR, activated partial thromboplastin time (aPTT), fibrinogen, and functional and immunologic levels of factors VII, IX, and X. Both aPTT and fibrinogen correlated with INR in patients with SAC, but not in patients treated with warfarin. Factors VII, IX, and X showed an inverse relationship with INR in the anticoagulated patients; however, no relationship between factor level and INR was observed in patients with SAC. Distinct patterns of coagulopathy were observed in patients with SAC and patients receiving warfarin anticoagulation, and equivalent INR values were associated with distinct coagulation profiles in the two patient groups. These results suggest that an abnormal INR provides different information about the coagulation status in patients with disseminated intravascular coagulation than in patients receiving warfarin. This may indicate that an equivalently increased INR predicts different bleeding risks in these two patient groups.
凝血异常在脓毒症患者中很常见。脓毒症相关凝血病(SAC)通常通过凝血酶原时间(PT)延长或国际标准化比值(INR)升高并伴有血小板计数降低来诊断。INR也用于监测接受华法林治疗的患者。然而,由于SAC和华法林抗凝的性质不同,相同的INR值在这两类患者群体中可能提供不同的信息。本研究的目的是比较SAC患者与接受华法林抗凝治疗患者的凝血功能指标和凝血因子水平。在基线时从诊断为SAC的患者和接受华法林治疗的患者中收集去识别化的血浆样本。对这些血浆样本进行PT/INR、活化部分凝血活酶时间(aPTT)、纤维蛋白原以及因子VII、IX和X的功能和免疫水平评估。在SAC患者中,aPTT和纤维蛋白原均与INR相关,但在接受华法林治疗的患者中并非如此。在接受抗凝治疗的患者中,因子VII、IX和X与INR呈负相关;然而,在SAC患者中未观察到因子水平与INR之间的关系。在SAC患者和接受华法林抗凝治疗的患者中观察到不同的凝血病模式,并且在这两个患者组中,相同的INR值与不同的凝血谱相关。这些结果表明,异常的INR在弥散性血管内凝血患者和接受华法林治疗的患者中提供了关于凝血状态的不同信息。这可能表明,同等程度升高的INR在这两类患者组中预测不同的出血风险。